IP Verse

Merck Sharp & Dohme Llc opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Merck Sharp & Dohme Llc

Patent Number:
EP3597659
Title:
Prevention Of Disulfide Bond Reduction During Recombinant Production Of Polypeptides
Applicant:
GENENTECH, INC.
Opposition Date:
Dec 1, 2023
Patent Number:
EP3597216
Title:
Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses Thereof
Applicant:
E. R. SQUIBB & SONS, L.L.C.
Opposition Date:
Apr 27, 2023
Patent Number:
EP3760715
Title:
Large-Scale Production Of Soluble Hyaluronidase
Applicant:
HALOZYME, INC.
Opposition Date:
May 4, 2022
Patent Number:
EP3322731
Title:
Method Of Treating Cancer Using Immune Checkpoint Inhibitor
Applicant:
BRISTOL-MYERS SQUIBB COMPANY
Opposition Date:
Oct 12, 2021
Patent Number:
EP2382228
Title:
Compositions And Methods Of Treating Inflammatory And Autoimmune Diseases
Applicant:
AMGEN INC.
Opposition Date:
May 26, 2021
Patent Number:
EP2949666
Title:
Human Anti-Alpha-Synuclein Antibodies
Applicant:
BIOGEN INTERNATIONAL NEUROSCIENCE GMBH
Opposition Date:
Sep 19, 2019
Patent Number:
EP1810026
Title:
B7-H1 And Methods Of Diagnosis, Prognosis, And Treatment Of Cancer
Applicant:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Opposition Date:
Jan 16, 2019
Patent Number:
EP2188371
Title:
Use Of Perfusion To Enhance Production Of Fed-Batch Cell Culture In Bioreactors
Applicant:
WYETH LLC
Opposition Date:
Sep 20, 2018
Patent Number:
EP2188302
Title:
Prevention Of Disulfide Bond Reduction During Recombinant Production Of Polypeptides
Applicant:
GENENTECH, INC.
Opposition Date:
Aug 1, 2018
Patent Number:
EP2958588
Title:
Combination Of Vaccination And Inhibition Of The Pd-1 Pathway
Applicant:
CUREVAC AG
Opposition Date:
May 23, 2018

Latest patents of Merck Sharp & Dohme Llc opposed by its competitors

Patent:
EP3283882
Grant Date:
Oct 16, 2024
Title:
Blood-Based Biomarkers Of Tumor Sensitivity To Pd-1 Antagonists
Oppositions:
1
Patent:
EP3498734
Grant Date:
Sep 1, 2021
Title:
Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer
Oppositions:
7
Patent:
EP3391890
Grant Date:
Aug 25, 2021
Title:
Posaconazole Intravenous Solution Formulations Stabilized By Substituted Beta-Cyclodextrin
Oppositions:
4
Patent:
EP2970916
Grant Date:
Apr 14, 2021
Title:
Adapted Lepidopteran Insect Cells For The Production Of Recombinant Proteins
Oppositions:
2
Patent:
EP3036256
Grant Date:
Oct 28, 2020
Title:
Modulation Of Tumor Immunity
Oppositions:
2
Patent:
EP2935329
Grant Date:
Sep 16, 2020
Title:
Antibodies That Bind To Human Programmed Death Ligand 1 (Pd-L1)
Oppositions:
2
Patent:
EP3057612
Grant Date:
May 6, 2020
Title:
Method Of Obtaining Thermostable Dried Vaccine Formulations
Oppositions:
1
Patent:
EP2399588
Grant Date:
Apr 29, 2020
Title:
Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral Polymerase
Oppositions:
1
Patent:
EP3043797
Grant Date:
Apr 8, 2020
Title:
Treating Infections With Ceftolozane/Tazobactam In Subjects Having Impaired Renal Function
Oppositions:
1
Patent:
EP3079772
Grant Date:
Feb 5, 2020
Title:
Immunohistochemical Proximity Assay For Pd-1 Positive Cells And Pd-Ligand Positive Cells In Tumor Tissue
Oppositions:
1

Competitors of Merck Sharp & Dohme Llc

KONIG SZYNKA TILMANN VON RENESSE

PAJARO LIMITED

GENENTECH, INC.

Want to track Merck Sharp & Dohme Llc?

Feel free to send us a message here and we will get back to you